Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, will publish its interim report for the third quarter of 2026 on Monday 2 November at 08:30 CET. A webcast presentation will be held the same day at 15:00 CET. The presentation will be given by CEO Jeff Borcherding.

The presentation will be held in English and followed by a Q&A session. Follow the webcast via the link below:
https://events.teams.microsoft.com/event/1274ea2b-3f72-42e8-b9bb-128cd05bf932@4108bd4b-5f9f-40d6-bfff-a07cc8682f85?source=copyLinkOneEventsShareDialog

The report, together with the presentation slides, will be available at www.investors.immunovia.com.

For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit. www.immunovia.com.

Attachments
Immunovia invites to the presentation on the Q3 report 2026

Läs mer på MFN